Clinical impact of early minimal residual disease detection at day 15 in precursor B-childhood acute lymphoblastic leukemia: an Egyptian experience

Egyptian Journal of Medical Human Genetics

Table 4 MRD study of all patients on day 15 regarding studied parameters

Parameters		MRD result (Outcome at day 15)				Fisher exact test
		Good outcome, negative MRD (n= 44) 61.1%		Bad outcome, positive MRD (n= 28) 38.8%		Pvalue	Sig.
		N	%	N	%	Pvalue	Sig.
Studied cytogenetics at diagnosis	Positive	4	8.1%	12	42.8%	< 0.001	S
Studied cytogenetics at diagnosis	Negative	40	90.9%	16	57.2%	< 0.001	S
Risk classification	High risk	16	36.4%	24	85.7%	< 0.001	S
Risk classification	Standard risk	28	63.6%	4	14.3%	< 0.001	S
Age	< 1	2	4.5%	6	21.4%	0.036	S
	1–9	40	91.0%	6	21.4%
	> 10	2	4.5%	16	57.2%
Sex	Male	16	36.4%	18	64.2%	0.104	NS
Sex	Female	28	63.6%	10	35.8%	0.104	NS
Hepatomegaly	Absent	20	45.4%	12	42.8%	0.257	NS
Hepatomegaly	Present	24	54.5%	16	57.2%	0.257	NS
Splenomegaly	Absent	22	50.0%	14	50.0%	0.228	NS
Splenomegaly	Present	22	50.0%	14	50.0%	0.228	NS
Lymphadenopathy	Absent	4	8.1%	12	42.8%	1.000	NS
Lymphadenopathy	Present	40	90.9%	16	57.2%	1.000	NS
CNS infiltration	Absent	42	95.5%	22	78.6%	0.207	NS
CNS infiltration	Present	2	4.5%	6	21.4%	0.207	NS
Laboratory parameters
Parameters						ttest
Parameters		Mean	SD	Mean	SD	Pvalue	Sig
Hb (gm/dL)		8.32	1.44	7.55	0.91	0.178	NS
TLC (× 10⁹/L)		1.79	0.76	1.13	0.51	0.027	S
Platelets (× 10⁹/L)		102.32	56.74	61.75	23.12	0.014	S
BM blasts (%)		1.93	0.86	15.25	5.6	< 0.001	S

N number, NS non-significant, S significance. P ≥ 0.05 = NS; P < 0.05 = S; P ˂ 0.01 = HS; SD standard deviation, TLC total leukocytic count, Hb hemoglobin, BM bone marrow